Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670598 | 1.00 | HIF1A (0.67) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL28526434 | 1.00 | HIF1A (0.67) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL797544 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL5564783 | 0.95 | HIF1A (0.60) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL1894089 | 0.83 | CXCR4 (0.57) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL20523496 | 0.83 | — | — | |
| SCHEMBL23895059 | 0.82 | — | — | |
| Piperazine SCHEMBL734764 | 0.82 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL3999265 | 0.82 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL5033222 | 0.82 | HIF1A (1.00) | HIF1AMAPTPDE4AKDRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317796-A | EGFRvIII targeting compounds and uses thereof | 加拿大国立研究院 | 2024-07-09 | — | — | CN | claimed |
| EP-3773670-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| WO-2019195384-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | claimed |
| EP-4493578-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | Peter MacCallum Cancer Institute (AU) | 2025-01-22 | — | — | EP | disclosed |
| US-20240391849-A1 | RADIOLABELING OF POLYPEPTIDES | JANSSEN BIOTECH, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240254092-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| CN-118317796-A | EGFRvIII targeting compounds and uses thereof | 加拿大国立研究院 | 2024-07-09 | — | — | CN | disclosed |
| EP-4387667-A1 | COMBINATION RADIOTHERAPY | Telix Pharmaceuticals (Innovations) Pty Ltd (AU) | 2024-06-26 | — | — | EP | disclosed |
| US-11975081-B2 | Bifunctional chelators and conjugates | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240082438-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2024044551-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-3638320-A2 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2020-04-22 | — | — | EP | disclosed |
| WO-2019195384-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018222987-A1 | TARGETED CONSTRUCTS | TARVEDA THERAPEUTICS, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018204872-A2 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2018-11-08 | — | — | WO | disclosed |
| US-6995247-B2 | Ac-HEHA and related compounds, methods of synthesis and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040184991-A1 | Ac-HEHA and related compounds, methods of synthesis and methods of use | THE GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DPT. OF HEALTH AND HUMAN SERVICES | 2004-09-23 | — | — | US | disclosed |
| EP-1227849-A2 | ACTINIUM-225 COMPLEXES AND CONJUGATES FOR RADIOIMMUNOTHERAPY | Ma, Dangshe (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001066155-A2 | ACTINIUM-225 COMPLEXES AND CONJUGATES FOR RADIOIMMUNOTHERAPY | MA DANGSHE (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2000059896-A1 | 225Ac-HEHA AND RELATED COMPOUNDS, METHODS OF SYNTHESIS AND METHODS OF USE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391849-A1 | RADIOLABELING OF POLYPEPTIDES | PTMS, DNPEP, ANPEP | HIF1A 3707/4885MAPT 2422/4885PDE4A 3662/4885 |
| US-20240254092-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | FOLH1, PAICS, TAP2 | HIF1A 745/4885MAPT 4227/4885PDE4A 4754/4885 |
| US-20040184991-A1 | Ac-HEHA and related compounds, methods of synthesis and methods of use | APEH, DOHH, DDAH1 | HIF1A 1186/4885MAPT 4040/4885PDE4A 3191/4885 |
| US-11975081-B2 | Bifunctional chelators and conjugates | FOLH1, PAICS, TAP2 | HIF1A 745/4885MAPT 4227/4885PDE4A 4754/4885 |
| US-20240082438-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | FOLH1, PAICS, TAP2 | HIF1A 745/4885MAPT 4227/4885PDE4A 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.